Company news
Anaptysbio, Inc. (NASDAQ:ANAB) news
Anaptysbio, Inc. news releases on 6ix. Latest, Sep 21, 2026: AnaptysBio : Annual Transition Report (Form 10-KT)
Press releases & updates
AnaptysBio : Annual Transition Report (Form 10-KT)
September 21, 2026
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
May 11, 2026
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
May 4, 2026
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
April 28, 2026
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
April 24, 2026
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
April 20, 2026
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
March 26, 2026
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
March 26, 2026
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
March 26, 2026
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
March 3, 2026
Anaptys Announces Participation at Upcoming Investor Conferences
February 5, 2026
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
January 8, 2026
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
December 15, 2025
Anaptys Announces Participation in December Investor Conferences
November 24, 2025
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
November 20, 2025
Anaptys Announces $100 Million Stock Repurchase Plan
November 20, 2025
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
November 9, 2025
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
November 3, 2025
Anaptys Announces Participation in November Investor Conferences
November 3, 2025
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
October 28, 2025
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
October 12, 2025
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
September 28, 2025
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
September 28, 2025
Anaptys Announces Participation in September Investor Conferences
August 26, 2025
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
August 5, 2025
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
June 2, 2025
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
May 26, 2025
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
May 4, 2025
Anaptys Announces Stock Repurchase Plan
March 23, 2025
Anaptys Announces Participation in March Investor Conferences
February 26, 2025
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 26, 2025
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
February 11, 2025
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
February 10, 2025
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
February 2, 2025
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
February 2, 2025
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
December 10, 2024
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
November 4, 2024
Anaptys Announces Participation in November and December Investor Conferences
November 4, 2024
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
August 13, 2024
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
August 4, 2024
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
May 8, 2024
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
May 8, 2024
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Actym Therapeutics Appoints Thomas Smart as CEO
April 23, 2024
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 10, 2024
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
February 28, 2024